About Generalized Myasthenia Gravis (gMG) | IMAAVY® (nipocalimab-aahu) HCP

FcRn sustains autoantibody concentration

FcRn recycling pathway: FcRn binds IgG in acidified endosome, releases at physiological pH

FcRn is a protein that plays a crucial role in regulating IgG antibody levels in the body. By recycling IgG, FcRn helps maintain antibody levels in the bloodstream.¹

However, in autoimmune diseases like gMG, this function can inadvertently sustain pathogenic antibodies that drive disease activity.¹

FcRn pathway: Unbound IgG, both normal and pathogenic, is sent to the lysosome for degradation, while FcRn is sorted separately

An FcRn blocker is a targeted therapy that disrupts the IgG recycling process. By blocking FcRn, this type of treatment reduces circulating IgG, specifically lowering IgG, including pathogenic antibodies that contribute to symptoms in gMG.¹

FcRn=neonatal fragment crystallizable receptor;
IgG=immunoglobulin G.

gMG autoantibodies mistakenly target essential proteins on the postsynaptic membrane¹

gMG subtypes vary based on the specific autoantibodies involved, influencing disease severity and response to treatment. IgG autoantibodies cause disrupted neuromuscular communications and result in muscle weakness, a primary symptom of gMG.² Types of IgG antibodies in gMG can include: